Abstract
Despite substantial progress in pediatric cancer treatment, poor prognosis remained for patients with recurrent or metastatic disease, given the limitations of approved targeted treatments and immunotherapies. RNA therapeutics offer significant potential for addressing a broad spectrum of diseases, including cancer. Advances in manufacturing and delivery systems are paving the way for the rapid development of therapeutic RNAs for clinical applications. This review summarizes therapeutic RNA classifications and the mechanisms of action, highlighting their potential in manipulating major cancer-related pathways and biological effects. We also focus on the pre-clinical investigation of RNA molecules with efficient delivery systems for their therapeutic potential targeting pediatric solid tumors.
| Original language | English |
|---|---|
| Article number | 104406 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 200 |
| DOIs | |
| Publication status | Published - Aug 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 9 Industry, Innovation, and Infrastructure
Keywords
- Childhood cancer
- Delivery
- Mechanism of action
- Precision medicine
- RNA drugs
- Therapeutics
Fingerprint
Dive into the research topics of 'Targeting pediatric solid tumors in the new era of RNA therapeutics'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver